scispace - formally typeset
Open AccessJournal ArticleDOI

Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT)

Reads0
Chats0
TLDR
In this paper, a review of the published evidence for management and/or prevention of a given condition is carried out by experts in the field and a critical evaluation of diagnostic and therapeutic procedures is performed including assessment of the risk/benefit ratio.
Abstract
Guidelines and Expert Consensus Documents summarize and evaluate all currently available evidence on a particular issue with the aim to assist physicians in selecting the best management strategies for a typical patient, suffering from a given condition, taking into account the impact on outcome, as well as the risk/benefit ratio of particular diagnostic or therapeutic means. Guidelines are no substitutes for textbooks. The legal implications of medical guidelines have been discussed previously. A great number of Guidelines and Expert Consensus Documents have been issued in recent years by the European Society of Cardiology (ESC) as well as by other societies and organizations. Because of the impact on clinical practice, quality criteria for development of guidelines have been established in order to make all decisions transparent to the user. The recommendations for formulating and issuing ESC Guidelines and Expert Consensus Documents can be found on the ESC website (http://www.escardio.org/knowledge/guidelines). In brief, experts in the field are selected and undertake a comprehensive review of the published evidence for management and/or prevention of a given condition. Unpublished clinical trial results are not taken into account. A critical evaluation of diagnostic and therapeutic procedures is performed including assessment of the risk/benefit ratio. Estimates of expected health outcomes for larger societies are included, where data exist. The level of evidence and the strength of recommendation of particular treatment options are weighed and graded according to predefined scales, as outlined in Tables 1 and 2 . View this table: Table 1 Classes of recommendations View this table: Table 2 Levels of evidence The experts of the writing panels have provided disclosure statements of all relationships they may have which might be perceived as real or potential sources of conflicts of interest. These disclosure forms are kept on file at the European Heart House, headquarters of the ESC. Any changes in conflict of interest that arise …

read more

Content maybe subject to copyright    Report

Citations
More filters
Journal ArticleDOI

Left Ventricular Diastolic Dysfunction Predicts Mortality in Patients With Systemic Sclerosis

TL;DR: Diastolic function was assessed in a large, unselected SSc cohort and the presence of DD is associated with high mortality, and DD exceeds PH with respect to predicting mortality.
Journal ArticleDOI

Fundamentals of aerosol therapy in critical care

TL;DR: This review identifies the relevant factors which require attention for optimization of aerosol drug delivery that can achieve better drug concentrations at the target sites and potentially improve clinical outcomes.
Journal ArticleDOI

Functional impact of pulmonary hypertension due to hypoventilation and changes under noninvasive ventilation

TL;DR: In this specific cohort with hypoventilation and severe pulmonary hypertension, pulmonary hypertension was associated with reduced exercise capacity and following noninvasive ventilation, haemodynamics and exercise capacity improved significantly.
Journal ArticleDOI

Pathophysiological roles of nuclear factor kappaB (NF-kB) in pulmonary arterial hypertension: effects of synthetic selective NF-kB inhibitor IMD-0354

TL;DR: It is speculated that the positive-feedback loop (Erk1/2-NF-kB-MCP-1-Erk 1/2) is associated with progression of PAH by causing FGF₂-induced inflammation in MCT rats and has potential as a new therapeutic tool for PAH.
References
More filters
Related Papers (5)